Analyst Ratings For OncoSec Medical Inc (NASDAQ:ONCS)

Today, HC Wainwright set its price target on OncoSec Medical Inc (NASDAQ:ONCS) to $4.00 per share.

There are 4 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on OncoSec Medical Inc (NASDAQ:ONCS) is Buy with a consensus target price of $4.3333 per share, a potential 249.46% upside.

Some recent analyst ratings include

• 7/16/2018-Dawson James Reiterated Rating of Buy.
• 2/9/2018-Piper Jaffray Companies initiated coverage with a Overweight rating.
• 6/14/2017-Noble Financial Reiterated Rating of Buy.
• 12/28/2016-Ci Capital initiated coverage with a Buy rating.

Recent Insider Trading Activity For OncoSec Medical Inc (NASDAQ:ONCS)
OncoSec Medical Inc (NASDAQ:ONCS) has insider ownership of 5.50% and institutional ownership of 25.96%.

• On 7/5/2018 Avtar S Dhillon, Director, sold 37,575 with an average share price of $1.39 per share and the total transaction amounting to $52,229.25.
• On 7/5/2018 Richard B Slansky, CFO, sold 84,984 with an average share price of $1.39 per share and the total transaction amounting to $118,127.76.
• On 6/29/2018 Punit Dhillon, Director, sold 5,401 with an average share price of $1.38 per share and the total transaction amounting to $7,453.38.
• On 6/29/2018 Richard B Slansky, CFO, sold 2,420 with an average share price of $1.38 per share and the total transaction amounting to $3,339.60.
• On 6/27/2018 Punit Dhillon, Director, sold 17,480 with an average share price of $1.37 per share and the total transaction amounting to $23,947.60.
• On 6/27/2018 Richard B Slansky, CFO, sold 7,832 with an average share price of $1.37 per share and the total transaction amounting to $10,729.84.
• On 6/25/2018 Punit Dhillon, Director, sold 1,021 with an average share price of $1.41 per share and the total transaction amounting to $1,439.61.

About OncoSec Medical Inc (NASDAQ:ONCS)
OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response in Phase 1 and 2 clinical trials for metastatic melanoma and triple-negative breast cancer. The company has also completed Phase II studies in metastatic melanoma (OMS-I100) and merkel cell carcinoma (OMS-I110). OncoSec Medical Incorporated has an investigator-sponsored clinical trial with the University of California, San Francisco to evaluate the safety and efficacy of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) in patients with low tumor-infiltrating lymphocyte (OMS-I102); and a clinical trial collaboration and drug supply agreement with Merck (known as MSD outside the United States and Canada) to evaluate the combination of its ImmuoPulse IL-12 with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a registration-directed Phase 2b clinical trial referred to as PISCES. This trial would evaluate the combination of therapies in patients with unresectable metastatic melanoma who have progressed. It also has a research collaboration with Avacta Group plc for gene delivery of therapeutic affimers. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in San Diego, California.

Recent Trading Activity for OncoSec Medical Inc (NASDAQ:ONCS)
Shares of OncoSec Medical Inc closed the previous trading session at 1,24 −0,020 1,59 % with 1.23 shares trading hands.